Posted by Michael Wonder on 27 Jun 2023
Allecra Therapeutics submits new drug application to the US FDA for Exblifep for the treatment of complicated urinary tract infections
27 June 2023 - Allecra Therapeutics announced today the submission of a new drug application to the US FDA for cefepime/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections.
Upon approval, the antibiotic combination will be marketed under the trademark name, Exblifep.
